BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tran MN, Kullar R, Goldstein EJC. Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. Expert Opinion on Investigational Drugs 2019;28:323-35. [DOI: 10.1080/13543784.2019.1581763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Xu WC, Silverman MH, Yu XY, Wright G, Brown N. Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. Bioorg Med Chem 2019;27:3209-17. [PMID: 31221610 DOI: 10.1016/j.bmc.2019.06.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
2 Dutta D, Jafri F, Stuhr D, Knoll BM, Lim SH. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. J Intern Med 2021;289:293-308. [PMID: 32910532 DOI: 10.1111/joim.13173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kullar R, Tran MN, Goldstein EJC. Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). J Exp Pharmacol 2020;12:371-84. [PMID: 33116952 DOI: 10.2147/JEP.S242959] [Reference Citation Analysis]
4 Nerber HN, Sorg JA. The small acid-soluble proteins of Clostridioides difficile are important for UV resistance and serve as a check point for sporulation. PLoS Pathog 2021;17:e1009516. [PMID: 34496003 DOI: 10.1371/journal.ppat.1009516] [Reference Citation Analysis]